Open-label non-blinded cohort study on anti-histaminic resistant chronic idiopathic urticaria in Western India

Subramanian Natarajan; Poonam Subramanian

doi:10.4103/ijd.ijd_718_21

Publication of IADVL, WB
Official organ of AADV

Indexed with Science Citation Index (E) , Web of Science and PubMed

IJD^®

Users online: 4629

Archives

Online Early

Coming Soon

Guidelines

Subscriptions

e-Alerts

ORIGINAL ARTICLE

Year : 2022 | Volume : 67 | Issue : 5 | Page : 518-523

Open-label non-blinded cohort study on anti-histaminic resistant chronic idiopathic urticaria in Western India

Subramanian Natarajan¹, Poonam Subramanian²
¹ Allergologist and Pulmonologist, Department of Pulmonary Medicine, The Lung Centre, Office No 404, 4^th Floor Marathon Chambers, P K Road, Mulund West, Mumbai, Maharashtra, India
² Allergologist and Pulmonologist, The Lung Centre, Office NO 104, First Floor Trinity Apartments, Uthalsar Road, Thane West, Maharashtra, India

Correspondence Address:
Subramanian Natarajan
Allergologist and Pulmonologist, The Lung Centre, Office No 404, 4^th Floor Marathon Chambers, P K Road, Mulund West, Mumbai - 400 080, Maharashtra
India

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/ijd.ijd_718_21

Introduction: Chronic idiopathic urticaria (CIU) is a chronic relapsing disease with hives for a period of six weeks or more. It has a significant impact on the physical and mental well-being of patients. Aims and Objectives: Open-label non-blinded study of over 600 patients diagnosed with CIU was done. The aim of the study was to observe the following: 1. Characteristics of patients of anti-histaminic resistant CIU, 2. Efficacy of cyclosporin and any adverse events in the study population and 3. Prognosis and relapse rates of these patients at the end of one year. Methods: Detailed history taking and guided clinical evaluation were done to include chronic resistant urticarias in the study and their clinical characteristics and prognosis were studied. Results: A total of 610 patients were diagnosed with CIU over a period of four years. Of these, 47 patients (7.7%) were diagnosed with anti-histaminic resistant urticaria. Of these, 30 patients (4.9%) who took treatment with cyclosporin at the above dosages were included in group 1. Rest 17 patients were in group 2 that were continued on anti-histaminics. Patients in cyclosporin group 1 showed a significant reduction in symptom scores as compared with group 2 at the end of six months. A lower need for corticosteroid therapy was noted in the cyclosporin group. Conclusion: Cyclosporin in low doses is very useful in anti-histaminic resistant urticaria with the duration of therapy being six months. It is cost-effective in low and medium-income countries and easily available.

[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	598

Printed	18

Emailed	0

PDF Downloaded	26

Comments	[Add]